SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?

Prete, Marcella; Favoino, Elvira; Catacchio, Giacomo; Racanelli, Vito; Perosa, Federico

doi:10.1016/j.autrev.2020.102559

Cited by 25 publications

(26 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, immunosuppressive therapy might be therapeutic options. Tocilizumab, a humanized monoclonal antibody against IL-6 receptor, and IVIG were reported to be options [4,5]. We used these drugs quickly when the patients exhibited ARDS.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia

et al. 2020

View full text Add to dashboard Cite

Novel coronavirus disease 2019 (COVID-19) is a highly infectious and deadly disease, spreading worldwide. There are limited data about the clinical course of end-stage renal disease (ESRD) patients infected with COVID-19. However, previous cohort studies showed a high mortality rate of ESRD patients infected with COVID-19. We report here two Japanese ESRD patients confirmed with severe COVID-19 pneumonia. Case 1 was a 60-year-old man with ESRD due to diabetic nephropathy who were infected with COVID-19 and exhibited acute respiratory distress syndrome (ARDS) requiring mechanical ventilation and intensive care unit (ICU) admission. He was treated with tocilizumab and intravenous immunoglobulin (IVIG). After 6 days of treatment in ICU, he was extubated. Case 2 was a 68-year-old woman undergoing maintenance hemodialysis for 17 years who also exhibited ARDS due to COVID-19. Her clinical course resembles case 1. Our experience of these two cases indicates that anti-cytokine therapy might be effective for severe COVID-19 pneumonia in ESRD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The potential utility of therapy with human immunoglobulin for intravenous use (IVIG) has been recently reported by our group [55], based on the similar etiology and inflammatory pathogenesis of SARS-CoV-2 infection to diseases for which the use of IVIG has already been approved by the FDA or EMA (Table 1) [56][57][58][59][60][61][62][63], or for which IVIG are employed off-label (Table 2) [30,, including viral or bacterial septic shock [91] and the autoinflammatory syndrome with MAS [91][92][93]. To dam inflammation, IVIG should be given at a dosage not exceeding 0.4 g/kg/day for three to five consecutive days (maximum total dosage is 2 g/kg) and the patient should be well hydrated.…”

Section: Immunological Rationale For Targeting the Immune System To Fmentioning

confidence: 99%

SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment

Prete

Favoino

Catacchio

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

The current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of its highly contagious nature, the great number of patients requiring intensive care therapy, and the high fatality rate. In the absence of specific antiviral drugs, passive prophylaxis, or a vaccine, the treatment aim in these patients is to prevent the potent virus-induced inflammatory stimuli from leading to the acute respiratory distress syndrome (ARDS), which has a severe prognosis. Here, the mechanism of action and the rationale for employing immunological strategies, which range from traditional chemically synthesized drugs, anti-cytokine antibodies, human immunoglobulin for intravenous use, to vaccines, are reviewed.

show abstract

“…In a very recent study, the administration of IVIG is recommended in COVID-19 patients, with or without MIS features, because it effects on the production of TNF-α and reduces the number of regulatory T cells, which control inflammation and T cell activation. All these therapeutic protocols could affect the cytokinemediated interstitial and alveolar wall edema in ARDS and consequently on the viral clearance [53].…”

Section: Potential Treatment Protocolsmentioning

confidence: 99%

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children with COVID-19

Sarzaeim

Rezaei

2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Since December 2019, the world has been exposed to a novel virus from the coronaviruses family, named coronavirus disease 2019 (COVID-19), which has affected the life of millions people around the world. This global pandemic causes a wide spectrum of clinical manifestation in children, adults, and elderly. One side of the spectrum in children is being asymptomatic and the other side is severe inflammatory symptoms. In this article, we describe the clinical manifestations, genetic background, and immune response of children with COVID-19, who are presented with severe multisystem inflammatory syndrome (MIS).

show abstract

SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?

Abstract: SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?

Cited by 25 publications

References 31 publications

Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia

Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia

SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children with COVID-19

Contact Info

Product

Resources

About